Price Alert

Wave Life Sciences Ltd. (WVE)

NASDAQ: WVE · Real-Time Price · USD

8.29

0.11 (1.34%)

At close: Sep 05, 2025, 3:59 PM

8.46

2.11%

After-hours: Sep 05, 2025, 07:18 PM EDT

1.34% (1D)

Bid	7.87
Market Cap	1.32B
Revenue (ttm)	93.95M
Net Income (ttm)	-129.87M
EPS (ttm)	-0.8
PE Ratio (ttm)	-10.36
Forward PE	-6.78
Analyst	Buy

Ask	8.55
Volume	2,765,380
Avg. Volume (20D)	1,672,867
Open	8.24
Previous Close	8.18
Day's Range	8.10 - 8.62
52-Week Range	5.04 - 16.74
Beta	-1.16

About WVE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol WVE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for WVE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Wave Life Sciences Ltd. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 days ago

-16.84%

Wave Life Sciences shares are trading lower. The c... Unlock content with Pro Subscription

1 month ago

+1.39%

Wave Life Sciences shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a price target of $19.

News

1 day ago · https://thefly.com

Wave Life Sciences price target lowered to $18 from $21 at Wells Fargo

Wells Fargo analyst Tiago Fauth lowered the firm's price target on Wave Life Sciences to $18 from $21 and keeps an Overweight rating on the shares after the company reported AATD data update for 200 a...

3 days ago · seekingalpha.com

Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript

Wave Life Sciences Ltd. (NASDAQ:WVE ) Positive RestorAATion-2 Clinical Data Update Transcript Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Chris...

3 days ago · benzinga.com

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.

1 month ago · fool.com

Wave (WVE) Q2 Revenue Drops 56%

1 month ago · seekingalpha.com

Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Erik Ingelsson - Chief Scientific Officer Kate Rausch - Head of Investor Relations ...

1 month ago · zacks.com

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.25 per share a year ago.

2 months ago · seekingalpha.com

Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months

Wave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying oppor...